• Georg Noll, Sarah Noll, and David Hürlimann.
• Heart Clinic Hirslanden Zurich, Zurich, Switzerland. Electronic address: georg.noll@hirslanden.ch.
• Semin. Hematol. 2014 Apr 1;51(2):139-46.

AbstractAtrial fibrillation (AF), the most frequent sustained arrhythmia, is associated with an increased risk of thromboembolic events. The risk of stroke depends on risk factors such as age, hypertension, heart failure, and vascular disease. Thus, antithrombotic therapy is a cornerstone in the management of AF. Warfarin is successfully used to reduce thromboembolic events. More recently, direct thrombin (dabigatran) and factor Xa (apixaban, edoxaban, rivaroxaban) inhibitors have been compared to warfarin in large randomized trials. All new substances have been shown to be non-inferior to warfarin concerning thromboembolic events. Severe bleeding, such as fatal and intracranial bleeding, was less frequent with direct oral anticoagulants. Results of the studies and subgroup analyses are discussed. Further trials using direct oral anticoagulants in special populations such as very old and patients with kidney disease are needed.Copyright © 2014 Elsevier Inc. All rights reserved.

46 keywords...

hide…